Transglutaminase 2 Glycosaminoglycan
Introduction
Condensation of mesenchymal cells triggers their differentiation into chondrocytes and thus initiates the progression of chondrogenic differentiation through a sequential series of maturation stages, including a proliferation stage, pre-hypertrophic stage and terminal maturation characterized by cell hypertrophy, extracellular matrix (ECM) calcification and 0925-4773/$ -see front matter Ó 2010 Elsevier Ireland Ltd. All rights reserved. doi:10.1016/j.mod.2010.11.007 resorption. Chondrocytes synthesize large amounts of specific ECM characterized by the presence of collagen type II and aggrecan that carries extensive post-translational modifications with sulfated polysaccharide chains called glycosaminoglycans (GAGs). GAG synthesis is the highest in proliferating chondrocytes, and slowly declines with advanced maturation (Ooira et al., 1974; Kim and Conrad, 1977) . Identification of the signaling pathways that regulate chondrocyte differentiation and ECM production is essential for the understanding of skeletal development and for advancement of therapeutics for diseases such as osteoarthritis. Specific proteins expressed at a particular chondrocyte differentiation stage regulate transition to the next stage acting as auto-and paracrine factors. Recent studies have identified extracellular enzymes transglutaminases (TGases) as such regulators (Aeschlimann et al., 1993; Nurminskaya et al., 2003; Johnson and Terkeltaub, 2005) .
Transglutaminases (TGs) catalyze Ca 2+ -dependent covalent e-(c-glytaminyl)lysyl intra-and inter-protein crosslinking.
The best studied enzyme -tissue TG, also called TG2 -also possesses GTPase/ATPase and deamidating activities in addition to the crosslinking activity (reviewed by Lorand and Graham (2003) ). Moreover, when externalized by a yet unknown mechanism, TG2 can act as an extracellular regulator of diverse signaling pathways. Thus, extracellular TG2 has been shown to regulate phospholipase Cd (Nakaoka et al., 1994) , cAMP-dependent protein kinase [PKA] (Nurminskaya et al., 2003) , b-catenin (Faverman et al., 2008) , integrin-dependent mitogen-activated protein kinase (Johnson and Terkeltaub, 2005; Tanaka et al., 2007) , and Src-p190/RhoGAP (Janiak et al., 2006) . The diversity of the signal transduction targets for extracellular TG2 is conferred by the ability of this enzyme to interact with a number of cell-surface receptors including a 1B adrenergic receptors (Nakaoka et al., 1994) , integrins (Akimov et al., 2000) , the atypical G-protein-coupled receptor GPR56 (Xu and Hynes, 2007) , VEGF receptor 2 (Dardik and Inbal, 2006) , and LRP5/6 receptors (Faverman et al., 2008) . Particular patterns of the TG2-interacting receptors probably determine the cell-specific effects of this multifunctional protein.
Only two transglutaminases among the nine mammalian enzymes (Lorand and Graham, 2003) , are expressed in cartilaginous and osseous tissues. These are TG2 and a homodimeric form of the circulating heterodimeric coagulation factor FXIII (Aeschlimann et al., 1993; Nurminskaya and Linsenmayer, 1996) . These enzymes have very similar substrate specificity and both act as potent enhancers of terminal maturation in differentiating osteochondral cells in vitro (Aeschlimann et al., 1993; Nurminskaya et al., 1998; Johnson et al., 2008) . In vivo, in the developing cartilaginous anlage of endochondral bones, TG2 is markedly absent at the very early stages of chondrocyte differentiation but is expressed prior to chondrocyte hypertrophy (Thomazy and Davies, 1999; Nurminskaya and Kaartinen, 2006) , suggesting a stage-specific role for this protein. Intriguingly, no skeletal phenotype has been observed in either TG2 or FXIIIa knockout models (Nanda et al., 2001; Koseki-Kuno et al., 2003) , likely due to the ability of these two enzymes to compensate for each other. For example, in the TG2À/À knockout bone and cartilage tissues the total levels of transglutaminase activity remain unchanged due to compensatory activation of FXIIIa (Nurminskaya and Kaartinen, 2006; Tarantino et al., 2009) .
To overcome the complications associated with the genetic loss-of-function models and to obtain an insight into the role of transglutaminases in chondrogenesis, we combined a gain-of-function approach with pharmacological loss-offunction approach using chondrogenesis in micromasses of chick limb bud mesenchymal cells as a model. Here we show that forced expression of TG2 promotes transition into the pre-hypertrophic stage and down-regulates the key enzyme of protein glycosylation, xylosyltransferase 2, thus attenuating deposition of the cartilaginous ECM. Conversely, pharmacologic inhibition of endogenous transglutaminase activity results in increased GAG synthesis and enhanced expression of the early chondrogenic markers in the micromass cultures. These results suggest that down-regulation of GAG synthesis, characteristic of pre-hypertrophic chondrocytes may be regulated by the onset of endogenous TG2. Identification of TG2 as a novel autocrine negative regulator of matrix deposition provides the necessary background for improved cartilage regeneration and in vitro bioengineering. In addition, our results strongly implicate PKA signaling as a mediator of these effects of TG2, revealing a novel mechanism for PKA regulation in chondrocyte differentiation and further advancing the general understanding of the molecular pathways that orchestrate chondrogenesis.
Results

TG2 is expressed in pre-hypertrophic chondrocytes
To characterize the expression pattern of TG2 during the mesenchymal-to-chondrogenic transition and in early chondrogenesis, we measured by quantitative RT-PCR the TG2 transcript levels in chicken embryonic limb buds starting with the embryonic stages 21-22 (3½ days) prior to mesenchymal condensation, and through the stage 28 (5½-6 days) when the cartilaginous anlagen are already formed. Expression of the TG2 protein at the same stages was analyzed by immunolocalisation to tissue sections. This analysis shows that TG2 mRNA is up-regulated at stage 28 concomitant with accumulation of detectable amounts of the TG2 protein in the cartilaginous anlagen. Noteworthy, at this stage there are yet no hypertrophic collagen type X-positive chondrocytes ( Fig. 1A and B) (Schmid and Linsenmayer, 1985) , indicating the prehypertrophic nature of the TG2-positive cells. Thus, TG2 expression is induced during cell transition into pre-hypertrophy around day 6 of embryonic development, and even earlier than suggested previously (Thomazy and Davies, 1999) .
The in vivo pattern of TG2 expression in chondrogenesis is mirrored in the high-density cell cultures, defined as micromass cultures, in which chondrogenic differentiation in mesenchymal cells occurs spontaneously. The micromass culture system recapitulates in vitro the entire process of chondrogenesis including chondrocyte differentiation (days 1-10), growth and early differentiation (days 5-12), and maturation and hypertrophy (from day 12 on) (Daumer et al., 2004) . We observed a 2-3-fold induction in TG2 expression in the 6 days old avian micromass cultures which contain chondrocytes at the stages of growth and transition into pre-hypertrophy, and are collagen type X-negative (Fig. 1C) . Based on the pattern of TG2 expression, characterized by its rapid induction prior to the onset of hypertrophy both in vivo and in vitro, we hypothesize that TG2 regulates early steps of chondrogenesis including transition of differentiating chondrocytes to prehypertrophy.
2.2.
Over-expression of TG2 promotes chondrogenic differentiation in mesenchymal cells
To gain the insight into the role of TG2 at early stages of chondrogenesis, we overexpressed TG2 in the micromass cultures using the avian replication-competent retrovirus RCASBP(A). We took this approach because synthesis of the elevated amounts of TG2 by mesenchymal cells in the chondrogenic micromass cultures assures its normal externalization and cell surface/extracellular localization whereas purified TG2 has been unable to replicate some of the biological activities of the endogenous enzyme (discussed in Akimov et al. (2000) ). In addition, cellular expression of TG2 overcomes the potentially impaired diffusion of the recombinant protein through the cartilaginous matrix of differentiating micromasses in which heparin sulfate binds exogenous TG2 with high affinity (reviewed in Scarpellini et al. (2009) ). Therefore, a viral expression construct was designed to encode human TG2 tagged with the secretory pre-pro-trypsin 15aa sequence to ensure externalization of the recombinant protein, similarly to extracellular localization of endogenous TG2 in the cartilaginous matrix (Fig. 1B) , (Aeschlimann et al., 1993; Nurminskaya and Kaartinen, 2006) .
Mesenchymal cells from the day 3 chicken limb buds were mixed with concentrated retrovirus particles, and grown for up to 7 days in the high-density micromass cultures. In these experiments, RCASBP virus expressing GFP protein was used as a control for possible non-specific effects of viral infection, and to determine the time course of viral protein expression.
Monitoring GFP expression with fluorescent microscopy revealed appreciable levels of the virally expressed proteins in the infected micromass cultures on the third day after plating, preceding expression of endogenous TG2 by 3 days. Efficient secretion of the virus-expressed TG2 was confirmed by Western analysis of the medium conditioned by the infected mesenchymal cells (Fig. 2A) . The secreted virus-derived TG2 is catalytically active, as demonstrated by the high levels of the transglutaminase activity in the growth medium of the RCAS-TG2 infected micromass versus the RCAS-GFP infected control (Fig. 2B) .
To characterize the impact of extracellular TG2 on the program of chondrogenic differentiation in micromasses, we analyzed expression of mesenchymal and chondrocyte molecular markers in 5 day-old micromass cultures infected with RCAS-TG2 using real-time PCR. Cultures infected with the control RCAS-GFP virus served as a reference. We found that extracellular TG2 stimulates mesenchymal cell , as evidenced by the reduced expression of the mesenchymal markers, pouV, TERT, Nanog, and increased expression of Sox9 which is a marker of chondrogenic commitment (Fig. 3A , gray bars versus black bar). However, expression of the molecules characteristic for chondrocyte growth, including collagen type II and aggrecan, was not markedly affected by the excess TG2. Instead, we observed up-regulation of the typical markers of pre-hypertrophic chondrogenic maturation including Ihh, Cbfa1 and plasma transglutaminase FXIIIA (Fig. 3B, black bars) . Similarly, Ncadherin, which is expressed at high levels in condensing mesenchymal cells (Oberlender and Tuan, 1994) , is significantly down-regulated about 50% (p < 0.05) in the cells infected with RCAS-TG2 (Fig. 3C ). These observations strongly suggest that excess TG2 accelerates progression of chondrocyte differentiation towards the pre-hypertrophic stage, causing accumulation of the pre-hypertrophic cells. Consistent with this model, excess TG2 does not induce markers of late hypertrophy such as the collagen type X and MMP13 even in older 8 day cultures (Fig. 3B , gray bars). Similarly, alkaline phosphatase activity is not induced by TG2 over-expression (Fig. 3C ). These results demonstrate that elevated levels of TG2 do not trigger precocious chondrocyte hypertrophy prior to its normal onset at about 12th day in micromass culture (Daumer et al., 2004) 2.3.
Over-expression of TG2 inhibits matrix production during micromass-induced chondrogenesis
To examine the effect of TG2 in early chondrogenesis we analyzed nodule formation in the infected micromasses. First, the number of nodules and the area of the GAG-positive Alcian Blue staining was analyzed in 5 day-old micromasses when the nodules are small and distinct. This analysis revealed no difference in nodule number between the RCASGFP-and RCASTG2-infected micromasses (Fig. 4A ), indicating that initial cellular condensation, which occurs over the first 24 h of micromass initiation, was not affected by viral infections in agreement with accumulation of the virally expressed TG2 about 3 days after initial infection (Fig. 2) .
However, the average area of Alcian Blue staining per nodule was 15% smaller in the TG2-overexpressing cells (Fig. 4A ), indicating that nodule enlargement was reduced by the premature expression of TG2. This difference becomes even more pronounced over time, and in the 7 days micromass cultures GAG-positive deposition in the RCASTG2-infected cells is dramatically reduced compared to control RCASGFP cells (Fig. 4B) . At the same time, cell proliferation is not affected by TG2 expression (Fig. 4C) , suggesting TG2 is a negative regulator of the cartilaginous ECM deposition.
2.4.
TG2 down-regulates xylosyltransferases, the key enzymes responsible for sulfated proteoglycan biosynthesis Histological analysis confirmed the reduced amount of the intercellular Alcian Blue-positive extracellular matrix, and showed a dense arrangement of cells in the RCAS-TG2 infected micromass cultures. For comparison, characteristic cartilage morphology with abundant basophilic matrix separating individual cells was observed in the control RCAS-GFP infected micromasses (Fig. 5A ). Taking into consideration that TG2 does not significantly affect transcript levels of aggrecan which is the core protein of the major sulfated cartilage proteoglycan ( Fig. 3B ), we hypothesized that TG2 negatively regulates aggrecan glycosylation and/or sulfation. We analyzed the effect of TG2 on expression of the key enzymes required for biosynthesis of glycosaminoglycan chains and for sulfation of glycosaminoglycans, including xylosyltransferases 1 and 2, chondroitin 6-sulfotransferase 3, and chondroitin 4-sulfotransferase 11, as well as the Link1 protein participating in proteoglycan assembly (Woods et al., 2007) . We found that TG2 markedly down-regulates transcript levels of xylosyltransferase 2 (Xytl2) and to a lesser extent of Link1 (Fig. 5B ). The xylosyltranferase enzymatic activity is also decreased in the TG2-overexpressing cultures (Fig. 5C ), supporting the hypothesis that TG2 negatively regulates deposition of the cartilaginous matrix in differentiating micromass cultures by attenuating the post-translational modification of matrix proteins such as aggrecan. 
TG2 inhibits PKA signaling in mesenchymal cells undergoing chondrogenic differentiation
Previously, we have shown that extracellular TG2 inhibits PKA activity in osteoblasts (Nurminskaya et al., 2003) . We therefore asked whether excess TG2 similarly attenuate PKA signaling in early chondrocytes and whether this pathway mediates the TG2-dependent inhibition of GAG synthesis in the micromass cultures. Using ELISA-based and radiometric assays, we detected a significant 1.7-fold decrease in the PKA activity in the RCAS-TG2 infected cultures as compared to the RCAS-GFP infected control (Fig. 6A) , demonstrating a correlation between the TG2-mediated inhibition of the PKA signaling and reduced ECM deposition. Analysis of the intracellular levels of cAMP in chondrifying infected cells revealed a significant 2-fold reduction in the cAMP levels (p < 0.01) in the presence of RCAS-TG2 (Fig. 6B , black bar versus gray RCAS-GFP bar). Moreover, a short 20 min exposure of the RCAS-GFP-infected cells to purified TG2 also results in a similar decrease in the cAMP levels (Fig. 6B , p < 0.05, white bar versus gray bar). These results implicate attenuation of the intracellular cAMP levels as a potential mechanism for the inhibition of PKA activity by extracellular TG2.
2.6.
PKA signaling may mediate the effects of TG2 on chondrogenesis in vitro Next, we analyzed the role of PKA signaling in the micromass-driven chondrogenesis. For this, we examined Alcian Blue staining of the micromass cultures grown for 5 days in the presence of two pharmacological inhibitors of PKA: KT5720 or H-89 (Fig. 6C) . Both inhibitors caused a significant 60-80% decrease in GAG deposition. While KT5720 is considered to be very specific for PKA, H-89 can also inhibit PKC, although at higher concentrations than were used in this study (Chijiwa et al., 1990) . To assure that the reduction of GAG deposition by H-89 did not dependent on PKC signaling, we employed the PKC specific inhibitor bisindolylmaleimide and observed only a minor 20% decrease in chondrogenesis (Fig. 6C, BIM) , implicating that strong attenuation of the cartilaginous GAG-rich matrix by H-89 is due to inhibition of PKA. We further analyzed the effect of H-89 on expression of xylosyltransferases in differentiating chondrocytes and found that, similarly to TG2, inhibition of PKA causes a drastic 75% down-regulation of Xylt 2 gene, p < 0.01 (Fig. 6D) .
TG2 inhibits cartilage formation independently of TGFb
Extracellular TG2 is able to activate latent TGFb (Nunes et al., 1997) which when overexpressed can inhibit chondrogenesis in cultured chick leg bud mesenchymal cells Carrington and Reddi, 1990; Jin et al., 2008; Mello and Tuan, 2006) . Therefore, we considered a possibility that activated TGFb signaling mediates the effects of TG2 on chondrogenesis. To explore this hypothesis, 2 day-old infected micromass cultures were transfected with the TGFb-dependent reporter construct in which luciferase is expressed under the SMAD2/SMAD3/SMAD4-regulated promoter (SABiosciences). There was no significant difference in luciferase expression 72 h after transfection between the RCAS-TG2 and RCAS-GFP infected micromasses (Fig. 7A) , indicating similar levels of the matrix-bound TGFb in micromasses with endogenous and elevated levels of TG2. In addition, we determined the levels of secreted active TGFb in the growth medium conditioned by these micromass cultures, using Cos-7 cells stably transfected with the TGFb-dependent luciferase reporter. Levels of luciferase activity were the same in the Cos-7 cells treated with medium from control or TG-overexpressing micromasses (data not shown). Together, these data indicate a TGFb-independent mechanism for the TG2-mediated regulation of the early stages of chondrogenesis.
2.8.
Role of MAPK signaling in TG2-dependent regulation of early chondrogenic differentiation Because extracellular TG2 can affect MAPK signaling (Janiak et al., 2006; Johnson and Terkeltaub, 2005) , we sought to investigate the potential effect of the elevated TG2 on the ERK1/2, p38, and JNK pathways which are the major conduits of the MAPK signaling pathway. Activity of MAPK/ ERK and MAPK/JNL was analyzed using specific luciferase reporters (SABiosciences). Excess TG2 has minor, if any, effect on MAPK/ERK activity in the 5 day-old micromasses, while causing an approximately 30% inhibition of JNK activity (Fig. 7A) . The activity status of the p38 pathway was determined by Western blot analysis for phosphorylated p38 protein. In the RCAS-TG2-infected cultures the p38 pathway is activated (Fig. 7B) . Next, we analyzed whether p38 kinase regulates xylosyltransferase expression similarly to TG2. Pharmacological inhibition of p38 results in a significant 58% down-regulation of Xylt2 mRNA, p < 0.01 (Fig. 7C) , indicating that p38 is a positive regulator of Xylt2 in contrast to TG2. These data suggest that the TG2-dependent regulation of GAG synthesis is not mediated by either ERK or p38 signaling pathways. Further experiment will access the role of JNK inhibition in the TG2-reliant chondrocyte differentiation.
2.9.
Loss-of-function analysis
To examine whether the effects of the overexpressed human TG2 on chondrocyte differentiation reflect the role of endogenous enzyme, we complemented the gain-of-function studies with the loss-of-function approach by inhibiting the endogenous transglutaminase activity with small-molecule irreversible TGase inhibitor ERW-1069 (Watts et al., 2006) . The 30 lM ERW1069 inhibits total transglutaminase activity in the micromasses down to approximately 60% (from 28 ± 4.3 to 17.4 ± 1.2 U/mg, p = 0.007). Continuous presence of the same concentration of ERW1069 in growing micromass cultures starting from day 2 causes a 20% increase in GAG deposition (p < 0.05) (Fig. 8A) , and a significant increase in Xylt2 expression (p < 0.05) (Fig. 8B) . These results are in accordance with the TG2-dependent inhibition of both Xylt2 expression and GAG deposition in the RCAS-TG2 infected micromasses and indicate that endogenous TG2 signaling regulates these processes (Figs. 4B and 5B) .
Next, we analyzed the effects of blocking the TGase activity on the progression of chondrocyte differentiation. Realtime PCR analysis revealed up-regulation of the early chondrogenic molecular markers, including Sox9, collagen type II and aggrecan, in the inhibitor-treated as compared to control untreated micromasses, while markers of pre-hypertrophy, such as Ihh, Cbfa1 and FXIIIa, were either slightly down-regulated or remained unaffected (Fig. 8C) . These results together with conclusions from the gain-of-function experiments (Section 2.2) demonstrate that TG2 regulates chondrocytes differentiation by promoting transition into pre-hypertrophy.
In vivo effects of TG2 on skeletal development
To extend the above findings to in vivo analysis, we determined the consequences of TG2 misexpression on long bone formation in the limb. To infect limbs, cell pellets of fibroblasts infected with retrovirus were micrografted into the wing bud between stages 18 and 19 (prior to the condensation of the cartilaginous anlagen). In these studies, contra lateral uninfected wing buds served as control. Embryos were collected at day 12 for anatomical analysis of skeletal development. Control grafting with RCAS-GFP virus revealed that expression of the target protein was found in the long bones, and surrounding mesenchyme, without any effect on their development (data not shown). On the contrary, grafting with RCAS-TG2 caused deregulation of long bone formation. One prominent phenotype consistently observed was the delay/ disruption of ossification, as indicated by the absence or reduction of Alizarin Red staining (Fig. 9A) . On average, TG2-induced a 60% reduction in the length of the ossifying region (n = 11) (Fig. 9B) , indicating retardation of endochondral ossification. The TG2-induced blocking of cells at more immature stage of pre-hypertrophy without acceleration of further development into hypertrophic cells would account for such phenotype. Consistent with this model, in the RCAS-TG2 infected right wing (compared to uninfected left wing) the pre-hypertrophic markers Ihh and Cbfa1 are significantly induced (Fig. 9C ) while hypertrophic markers MMP13 and collagen type X are slightly inhibited if changed at all. Thus, TG2 promotes chondrocyte transition into pre-hypertrophic stage both in vivo in the growth plate and in vitro in micromass cultures. 3.
Discussion
In this study, we show that extracellular enzyme transglutaminase 2 (TG2) is a novel autocrine regulator of cartilage formation. Previous work of the spatial and temporal expression pattern of TG2 in the embryonic growth plate implied that this protein promotes the transition of the differentiating chondrocytes into pre-hypertrophic stage. We addressed this hypothesis using the mesenchymal micromass-based model of the in vitro chondrogenesis which precisely recapitulates both the progression of chondrocyte differentiation and the TG2 expression profile. As a gain-of-function approach we employed the virus-driven expression of secreted TG2 several days earlier than induction of endogenous enzymes in differentiating micromasses. These studies were complemented with the loss-of-function approach by inhibiting the endogenous transglutaminases with a specific small molecule compound ERW-1069 (Watts et al., 2006) . Premature expression of TG2 up-regulates pre-hypertrophic markers including Ihh, Cbfa1 and FXIIIa (Nurminskaya and Linsenmayer, 2002) , while inhibition of endogenous transglutaminase promotes the expression of early chondrogenic markers, including Sox9, coll II and aggrecan. Cell proliferation is not affected by TG2 indicating that this enzyme regulates cell differentiation by promoting transition into the pre-hypertrophic stage. However, further maturation is not accelerated as evident by the inability of viral TG2 to induce hypertrophic markers collagen type X and MMP-13 in vitro and by the delay in endochondral ossification in vivo in the embryonic limbs infected with RCAS-TG2. The latter phenotype indicates blocking the chondrocytes at more immature stage of pre-hypertrophy without progression into hypertrophy. Similar up-regulation of the pre-hypertrophic molecular markers is also observed in vivo in the embryonic limbs infected with RCAS-TG2. Interestingly, collagen type II expression in vivo is to some extent induced by TG2, suggesting accumulation of both resting and prehypertrophic chondrocytes in the growth plate with disturbed chondrocyte maturation. Together, these data identify extracellular TG2 as a positive regulator of chondrocyte differentiation which promotes transition into the pre-hypertrophic stage. This activity of TG2 determines the importance of the TG2 paucity during the early stages of chondrogenic differentiation in the embryonic growth plate and in articular chondrocytes which remain in a resting state not undergoing full differentiation and in which TG2 normally is not expressed.
In addition to regulating gene expression in differentiating chondrocyte, TG2 regulates formation of the cartilaginous matrix. Premature expression of TG2 results in reduced deposition of the GAG-rich ECM, however, expression of the main ECM proteins collagen type II and aggrecan is not affected. This result suggests that TG2 attenuates ECM production by a specific mechanism, rather than by merely reducing the numbers of the cartilage-producing cells. Here we demonstrate that this mechanism involves TG2-induced down-regulation of the key enzyme of protein glycosylation -xylosyltransferase 2 (Xylt2), which regulates the initial step of GAG attachment to Ser residue of the core protein. The TG2-dependent coordinated down-regulation of xylosyltransferase activity and promotion of chondrocyte transition into pre-hypertrophic stage can explain, at least partially, the previously described reduced capacity for polysaccharide chain synthesis in maturing versus proliferating chondrocytes (Ooira et al., 1974; Kim and Conrad, 1977) .
In this study, we have identified that PKA signaling is a major molecular mechanism that mediates the TG2-dependent regulation of chondrogenic differentiation. First, we detect the TG2-induced reduction in cAMP levels and inhibition of PKA activity in differentiating micromasses. Not clear. A plausible model for the TG2-dependent inhibition of PKA, which needs further experimental evidence, suggests an involvement of yet unidentified cell-surface receptors that regulate intracellular adenylate cyclase activity controlling the intracellular levels of cAMP and are capable to bind extracellular TG2. The adrenergic receptors are credible candidates because they regulate cAMP levels (Cassel and Selinger, 1978) and bind TG2 (Chuang, 1984; Nakaoka et al., 1994) . Binding to TG2 induces internalization of adrenergic receptors (Chuang, 1984) , thus lowering the receptor levels on cell surface and resulting in a decrease in cAMP synthesis and in PKA inhibition. Next, we demonstrate that inhibition of PKA with specific pharmacological compounds is sufficient to mimic the effects of TG2 on Xylt2 expression and GAG deposition, in agreement with PKA signaling being the main intracellular intermediary of extracellular TG2.
In addition, inhibition of PKA may lead to activation of p38 kinase detected in the RCAS-TG2 infected micromass cultures, since PKA is known to destabilize the integrin-cytoskeletal complex required for efficient MAPK signaling (reviewed in Juliano (2002)). Although the p38 pathway is a positive regulator of chondrocyte differentiation (reviewed in Bobick and Kulyk (2008) and Zhen et al. (2001) ) and its activation is expected to correlate with the TG2-induced cell progression into pre-hypertrophic stage, the p38 pathway appears to positively regulate Xylt2 expression in contrast to TG2. This suggests that the TG2-induced reduction in GAG synthesis in mesenchymal cells undergoing chondrogenic differentiation is independent from p38 kinase, and that the p38 pathway may be a secondary target of extracellular TG2 downstream of PKA inhibition. This is in contrast to articular chondrocytes in which the TG2 effects appear to be mediated by the integrin-p38 pathway (Johnson and Terkeltaub, 2005) , and may be a reflection of the fact that signaling processes are often highly cell-context dependent. In the micromass model of chondrogenic differentiation, both endogenous TG2 and virus-derived TG2 are expressed several days after the initial condensation in early chondrogenesis, a process regulated by integrins. This pattern of expression suggests that TGase-mediated regulation of chondrocyte differentiation may be integrin-independent. Indeed, over-expression of TG2 does not activate either ERK1/2 or JNK kinases, in contrast to typical activation of these pathways by the integrin signaling (reviewed in Juliano (2002)). Moreover, we detect a TG2-dependent significant 30% inhibition in JNK activity in the chondrifying micromasses. Further experiments will address the role of JNK inhibition and possible interactions between PKA and JNK pathways in the TG2-reliant chondrocyte differentiation.
The novel ability of TG2 to regulate protein glycosylation, described here, may underlie the variety of biological activities of this enzyme, associated with normal development, wound healing, neurological and cardiovascular disease, as well as with cancer. The TG2-induced reduction in glycosylation may indirectly affect various signaling pathways since many transmembrane proteins engaged in signal transduction are glycosylated (reviewed in Juliano (2002) ). In addition, matrix GAG chains play a significant role in retention of various growth factors and morphogens. For example, GAGs have been implicated in the biological activity of hedgehog (Hh) proteins by localizing them to the extracellular space and conveying the Hh signal (Koziel et al., 2004; Dierker et al., 2009) . It is reasonable to suggest, that in the RCAS-TG2-infected micromasses reduced GAG content may lower the activity of Ihh even though this hypertrophy-promoting factor is up-regulated by TG2, and thus mediate blocking of the chondrocytes in the pre-hypertrophic stage without acceleration of cell hypertrophy.
In conclusion, our data provide an important insight into the mechanisms regulating proteoglycan synthesis in chondrogenesis. We have identified extracellular TG2 as a novel negative regulator of GAG synthesis. The proper deposition of the GAG-rich extracellular matrix determines cartilage stiffness to compression and its resilience. In addition, GAGs influence the function of numerous growth factors which affect chondrocytes. Thus, our findings highlight the importance of the TG2 paucity during the earliest stages of chondrogenesis and suggest that biological activity of TG2 in this developmental process must be tightly regulated, in agreement with in vivo expression of TG2 being restricted to pre-hypertrophic cartilage (Thomazy and Davies, 1999; Nurminskaya and Kaartinen, 2006) . The described inhibitory effect of TG2 on the deposition of cartilaginous matrix should be considered when TG2 is used in bioengineering as ''biological glue'' (Ehrbar et al., 2007; Jones and Messersmith, 2007; McHale et al., 2005) or in other capacity. PKA signaling is an important regulator of chondrogenesis in differentiating mesenchymal cells (Yoon et al., 2000; Za'ka'ny et al., 2002; Ciarmatori et al., 2007) , and identification of TG2 as a novel negative regulator of this pathway contributes to general understanding of the complex regulatory network orchestrating cartilage development and disease. Manipulations with TG2 and/or with the identified TG2-dependent signaling pathways will likely lead to advances in bioengineering of cartilage implants, and may prove instrumental for correction of developmental cartilage malformations.
4.
Experimental procedures
Chick embryos
Fertilized wild-type chicken eggs (White Leghorn; Poyndon Farm, UK; Charles River, USA) were incubated at 38°C and staged according to Hamburger and Hamilton (1951) .
4.2.
Viral construct for expression of secreted TG2
Viral construct for expression of secreted TG2 was created by inserting the coding sequence for the pre-pro-trypsin secretory peptide SALLILALVGAAVAA at the 5 0 -end of TG2
ORF, and insertion of the myc epitope-coding sequence GLEQ-KLISEEDL at the 3 0 -end of ORF. For this, the human TG2 ORF was modified using PCR-directed mutagenesis, by replacing the initiation Met codon with the Not I cleavage site and by replacing the termination codon with the Eag I cleavage site. The Not I/Eag I fragment comprising the TG2 ORF was cloned into the Cla I site of the RCASBP(A) vector with the help of synthetic double-stranded oligonucleotide adaptors TACGTGGGACGTGCAGCCGACCACCATGTCTGCACTTCTGATC CTAGCTCTTGTTGGAGCTGCAGTTGC (ligated at the 5 0 -end of ORF) and TGGAACAAAAACTCATCTCAGAAGAGGATCTGTAG (at the 3 0 -end). The adaptors had appropriate overhangs matching the sticky ends produced by endonuclease cleavage of the TG2 ORF fragment and vector. This procedure resulted in in-frame fusion of the TG2 ORF with sequences coding for the secretory peptide preceded by the new initiation Met codon, and for the myc epitope ending with the new termination codon. Placing the chimeric secreted myc-tagged TG2 ORF into the Cla I site of RCASBP(A) poised it for expression as a spliced mRNA driven by the ASLV promoter. The integrity of sequence cloned in RCASBP(A) was verified by sequencing. As a control for non-specific effects of viral infection, we used an RCASBP virus that encodes GFP (Clontech).
Micromass cultures
Micromass cultures were carried out as described (Logan and Francis-West, 2008 ) using stage 20/21 wing buds. Cells were plated at high density in the suspension of TG2-or GFP-encoding retrovirus (3-7 · 10 8 pfu/ml). The effect of TG2 over-expression on chondrogenesis was evaluated by staining the cartilaginous nodules in 6 day-old cultures with Alcian Blue. Briefly, cultures were fixed in 4% paraformaldehyde, washed and stained with 1% Alcian Blue (8GX) in 0.1 N HCl for 1 h. For quantitative assessment, the bound Alcian Blue was extracted with 1 ml 4 M guanidine hydrochloride for 1 h with shaking and optical density of the extract measured at 590 nm. Experiments were repeated in triplicate, with at least 3 micromasses in each replicate.
Cell proliferation
Cell proliferation was measured using the formazan-based color assay kit (MTT) (Promega) according to manufacturer's instructions.
Synthetic inhibitors
The protein kinase inhibitors (EMD Biosciences) were used as culture medium supplements throughout the micromass culture. Inhibitors were used either at their reported IC 50 for cultured cells or, if IC 50 values were not reported, at their Ki. Specifically, the following concentrations were used: the p38 kinase inhibitor SB203580 (10 lM), PKA inhibitors KT5720 (1 lM) and H-89 (100 nM), and PKC inhibitor bisindolylmaleimide I (10 nM) (all from Calbiochem). Transglutaminase inhibitor ERW-1069 (quinolin-3-ylmethyl(S)-1-(((S)-3-bromo-4,5-dihydroisoxazol-5-yl)methylamino)-3-(5-fluoro-1H-indol-3-yl)-1-oxopropan-2-ylcarbamate), kindly provided by Dr. C. Khosla (Stanford University) (Watts et al., 2006) , was used at 30 lM. Less than 10% cytotoxicity of the employed inhibitor concentrations was confirmed using lactate dehydrogenase release assay reagents (Roche).
4.6.
PKA activity PKA activity in the micromass cultures was assayed with SigmaTECTÒ Protein Kinase Assay System (Promega) and with ELISA-based kinase activity assay (EMD Biosciences) according to manufacturer's instructions.
4.7.
Transglutaminase activity
Transglutaminase activity in the cultured cells and in the medium was measured by incorporation of EZ-biotinpentilamine (Promega) into casein in microplates (Trigwell et al., 2004) .
4.8.
Alkaline phosphatase activity
Alkaline phosphatase activity in the cultured cells was measured by hydrolysis of p-nitrophenyl phosphate (Sigma), according to manufacturer's instructions.
4.9.
Quantitative assay for biologically active TGFb
Quantitative assay for biologically active TGFb was performed with a stable Cos-7 cell line that we established using the lentiviral TGFb-dependent luciferase Cignal reporter (Invitrogen). These reporter cells were treated for 48 h with medium conditioned by the RCAS-TG2 or RCAS-GFP infected micromass cultured of chick limb bud mesenchymal cells. Luciferase activity in the total cell lysates was measured with luciferase assay (Promega).
Analysis of cell signaling
Analysis of cell signaling including TGFb, MAPK/ERK, and MAPK/JNK pathways was performed using the plasmid-based Cignal luciferase reporters (Invitrogen). Mesenchymal cells were infected with RCAS-TG2 or RCAS-GFP, allowed to undergo chondrogenic differentiation for 7 days, and then transfected with the Cignal reporter plasmids according to the manufacturer's protocol. The b-galactosidase internal control pSV40-b-gal construct (Promega) was used as the transfection efficiency reference.
Real-time RT-PCR
Primers for detection of transcripts for TG2, N-cadherin, actin, L-19, xylosyltransferases 1 and 2, chondroitin 6-sulfotransferase 3, chondroitin 4-sulfotransferase, PouV, TERT and Nanog, coll II, coll X, F13, sox9, Cbfa1, MMp13, osteopontin, and beta-actin were designed with Oligo4.0 software. Four to five micromasses from independent experiments were analyzed in triplicates, using SYBR Green chemistry (Applied Biosystems) and iCycler IQ apparatus (Bio-Rad). Gene expression was normalized to beta-actin levels. Paired Student's t-test was used for statistical analysis.
cAMP assay
Mesenchymal cells were infected with either GFP-RCAS or TG2-RCAS and grown for 7 days. Some samples of infected cells were additionally exposed to 3 lg/ml purified guinea pig liver TG2 (Sigma) for 30 min. Cellular levels of cAMP were detected with cAMP-Glo assay kit (Promega).
Xylosyltransferase assay
Micromass cultures were lyzed in a buffer containing 1% Nonidet P-40, 150 mM NaCl, and 50 mM Tris-HCl, pH 7.8. Enzymatic activity was measured with the previously described mass spectrometric assay using a modified bikunin peptide as a substrate (Kuhn et al., 2006) .
Immunohistological analysis
Micromass or embryonic limbs were fixed for 15 min in 4% paraformaldehyde and 9-10 lm sections were cut with cryostat. For immunohistological analysis, sections were treated for 30 min at room temperature with 0.06% hyaluronidase solution to reveal collagen epitopes and blocked with 1% bovine serum albumin for 20 min. Anti-human TG2 antibody (Upstate, Inc.), was employed Rhodamine-conjugated secondary antibodies (Pierce) were used for visualization with fluorescent Nikon microscope. For histological analysis sections were stained with hematoxylin and Alcian Blue.
Culture and grafting of the retrovirus
Chick embryonic (O-line) fibroblasts (CEFs) were transfected with retroviral DNA (encoding TG2 or a control construct) as described previously (Logan and Francis-West, 2008) . After 7 days when the cells were fully infected, the CEFs were trypsinised from the culture plate, pelleted and allowed to consolidate for 1 h. The cell pellet was grafted into the right wing bud of stage 18/19 embryos and the embryos allowed to develop until day 10-14 during which time the replication-competent retrovirus spreads throughout the limb. Following manipulation, embryos were fixed at various time points, for skeletal analysis by Alcian Blue/Alizarin Red S staining (McLeod, 1980) . The lengths of the mineralized areas were measured in the treated and contralateral control limbs and the differences in the lengths were analyzed using a paired Student's t-test. For real-time PCR analysis radius bones were dissected from the right RCAS-TG2 infected and left control wings. The central parts of the radii, in which changes in mineralization were observed, were used for mRNA isolation and gene expression analysis, after confirmation of the virus-derived human TG2 expression by PCR.
